Date | Time | Source | Headline | Symbol | Company |
06/17/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer | NASDAQ:AZN | AstraZeneca PLC |
06/16/2024 | 7:00AM | Business Wire | CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
06/12/2024 | 5:35PM | Business Wire | FARXIGA approved in the US for the treatment of pediatric type-2 diabetes | NASDAQ:AZN | AstraZeneca PLC |
06/12/2024 | 10:14AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/10/2024 | 7:00AM | Business Wire | TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer | NASDAQ:AZN | AstraZeneca PLC |
06/06/2024 | 7:00AM | PR Newswire (US) | I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 4:23PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 10:02AM | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 9:10AM | IH Market News | Economic Worries May Lead To Weakness On Wall Street | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 7:00AM | PR Newswire (US) | AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 | NASDAQ:AZN | AstraZeneca PLC |
06/03/2024 | 10:29AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/03/2024 | 10:23AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/03/2024 | 6:35AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/02/2024 | 2:32PM | Business Wire | TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
06/02/2024 | 8:05AM | Business Wire | IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo | NASDAQ:AZN | AstraZeneca PLC |
06/02/2024 | 8:00AM | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy | NASDAQ:AZN | AstraZeneca PLC |
05/28/2024 | 4:30PM | GlobeNewswire Inc. | Cellectis Reports Financial Results for First Quarter 2024 | NASDAQ:AZN | AstraZeneca PLC |
05/28/2024 | 9:06AM | Business Wire | ダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示す | NASDAQ:AZN | AstraZeneca PLC |
05/28/2024 | 6:15AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
05/27/2024 | 4:55PM | Business Wire | Datopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem Lungenkrebs | NASDAQ:AZN | AstraZeneca PLC |
05/27/2024 | 1:14PM | Business Wire | Le datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameux | NASDAQ:AZN | AstraZeneca PLC |
05/27/2024 | 7:00AM | Business Wire | Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
05/23/2024 | 1:52PM | Business Wire | AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) | NASDAQ:AZN | AstraZeneca PLC |
05/23/2024 | 7:00AM | Business Wire | AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) | NASDAQ:AZN | AstraZeneca PLC |
05/22/2024 | 7:00AM | Business Wire | AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 | NASDAQ:AZN | AstraZeneca PLC |
05/21/2024 | 6:44PM | Business Wire | アストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定 | NASDAQ:AZN | AstraZeneca PLC |
05/21/2024 | 11:37AM | Business Wire | AstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 an | NASDAQ:AZN | AstraZeneca PLC |
05/21/2024 | 11:36AM | Business Wire | AstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030 | NASDAQ:AZN | AstraZeneca PLC |
05/21/2024 | 7:18AM | IH Market News | CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News | NASDAQ:AZN | AstraZeneca PLC |
05/21/2024 | 6:08AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |